Cytosorbents Corporation (CTSO) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, CTSO scores 22 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 4/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow scores 5/20 (institutional accumulation and options positioning); Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 4/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet scores 6/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 2.82).

For a prospective investor, the pillar profile points to weak cash generation as the central issue: a negative ROIC and a 0% FCF yield mean the business is not currently converting capital into free cash for shareholders. The forensic pillar reflects a leveraged balance sheet (Debt/Equity 2.82) and a Piotroski F-Score of 3 out of 9, which signals limited financial-quality strength. The Insider and 13F pillars are also low, indicating weak conviction signals in the available flow data. The main upside driver implied by the data is any sustained improvement in operating income, since the reported operating margin of -39.8% leaves substantial room for margin repair; however, the source data does not establish that such improvement is underway. Valuation tradeoffs are difficult to assess because P/E, Forward P/E, and EV/EBITDA are not available in source data. The market capitalization of $13.9M against FY 2025 debt of $16.7M illustrates how thin the equity cushion appears relative to liabilities. The 52-week range of $2.84 - $17 reflects extreme price volatility, which is consistent with the rating's forensic-risk label.

Per the SEC financials, net losses narrowed from $-29.2M in FY 2023 to $-8.2M in FY 2025, while revenue rose from $0.0M to $37.1M across the same span. Gross margin is reported at 71.5%, but operating margin is -39.8% and net margin is -22.1%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3 out of 9, with Debt/Equity at 2.82. These forensic readings indicate a balance sheet under meaningful strain with weak financial-quality signals.

Per the recent news and catalysts feed, the headlines include a TradingView estimates report, a Yahoo Finance UK seasonal returns chart, an Investing.com note that WBB Securities initiated coverage with a Speculative Buy rating, a Stock Titan item noting a live Q&A following third-quarter results on Nov. 12, a Kalkine report on scheduling Q3 2026 results, and a TradingView item stating a Q3'26 revenue estimate of 9.90M USD. All items are tagged with a YELLOW light and MARKET WIRE impact label. Key catalyst watch items are the Q3 2026 results and live Q&A on Nov. 12 and the revenue estimate of 9.90M USD. Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals recorded.

• What are the company's specific products, customers, and revenue drivers, given that the source data only provides sector classification?
• What are the trailing and forward earnings and valuation multiples, which are absent from the source data?
• What is the composition of the FY 2025 debt of $16.7M, including maturity schedule and covenant terms?
• What drove the revenue increase from $35.6M in FY 2024 to $37.1M in FY 2025, and what is the trajectory of operating losses?
• Who holds the shares, and is there any analyst coverage or insider activity beyond the single WBB Securities initiation headline?